CS6253: a novel peptide with the potential to lower the risk of Alzheimer’s disease
3:13
CS6253: a novel peptide with the potential to lower the risk of Alzheimer’s disease
7 сағат бұрын
PreventE4: evaluating the role of omega-3 in cognitive health and Alzheimer’s disease
4:42
PreventE4: evaluating the role of omega-3 in cognitive health and Alzheimer’s disease
7 сағат бұрын
The great debate: defining AD beyond amyloid-β
4:42
The great debate: defining AD beyond amyloid-β
7 сағат бұрын
Novel therapeutics being explored in AD and moving towards combination approaches
1:55
Novel therapeutics being explored in AD and moving towards combination approaches
7 сағат бұрын
Tyrosine kinase inhibitors in neurodegenerative diseases and lessons learned from cancer treatment
3:09
Tyrosine kinase inhibitors in neurodegenerative diseases and lessons learned from cancer treatment
7 сағат бұрын
Understanding agitation in Alzheimer’s disease and current approaches to management
3:31
Understanding agitation in Alzheimer’s disease and current approaches to management
9 сағат бұрын
Lecanemab: slowing the progression of AD and the potential for subcutaneous administration
3:26
Lecanemab: slowing the progression of AD and the potential for subcutaneous administration
Күн бұрын
Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial
2:13
Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial
Күн бұрын
The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD
1:43
The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD
Күн бұрын
The potential of targeting omega-3 metabolism in the brain to prevent AD
2:47
The potential of targeting omega-3 metabolism in the brain to prevent AD
Күн бұрын
The International Working Group’s new recommendations for diagnosing AD
6:25
The International Working Group’s new recommendations for diagnosing AD
Күн бұрын
A Phase II trial of nilotinib in patients with dementia with Lewy bodies
9:37
A Phase II trial of nilotinib in patients with dementia with Lewy bodies
Күн бұрын
An automated speech tool to screen for cognitive impairment: a study in four European cohorts
5:00
An automated speech tool to screen for cognitive impairment: a study in four European cohorts
Күн бұрын
The need for digital tools to assess cognition in Alzheimer's disease
2:09
The need for digital tools to assess cognition in Alzheimer's disease
Күн бұрын
Using blood testing to improve the accuracy of AD diagnosis in primary and secondary care settings
3:32
Using blood testing to improve the accuracy of AD diagnosis in primary and secondary care settings
14 күн бұрын
Comparing plasma ptau217 with CSF biomarkers for predicting tau PET status
1:02
Comparing plasma ptau217 with CSF biomarkers for predicting tau PET status
14 күн бұрын
The accuracy of plasma tau217 biomarkers in detecting AD pathology
2:27
The accuracy of plasma tau217 biomarkers in detecting AD pathology
14 күн бұрын
Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials
4:34
Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials
14 күн бұрын
The association between infectious diseases and dementia
6:13
The association between infectious diseases and dementia
14 күн бұрын
Highlights from AAIC 2024: tau-PET harmonization and the DIAN-TU trial
2:09
Highlights from AAIC 2024: tau-PET harmonization and the DIAN-TU trial
28 күн бұрын
The clinical use of tau-PET: its value and limitations
1:50
The clinical use of tau-PET: its value and limitations
28 күн бұрын
Improving tau-PET harmonization: the HEAD study
5:57
Improving tau-PET harmonization: the HEAD study
28 күн бұрын
Looking back over the first year of lecanemab use in AD: benefits and challenges
4:19
Looking back over the first year of lecanemab use in AD: benefits and challenges
28 күн бұрын
The minimum acceptable performance of blood biomarker tests for diagnosing AD
5:12
The minimum acceptable performance of blood biomarker tests for diagnosing AD
28 күн бұрын
A head-to-head comparison of AD blood tests reveals the value of ptau217
7:08
A head-to-head comparison of AD blood tests reveals the value of ptau217
28 күн бұрын
The evolution of biomarker testing in AD: CSF, blood, and PET
5:25
The evolution of biomarker testing in AD: CSF, blood, and PET
28 күн бұрын
Fueling dementia policy change on an international level
3:39
Fueling dementia policy change on an international level
Ай бұрын
The spread of oligomeric tau through synapses in Alzheimer's disease
8:11
The spread of oligomeric tau through synapses in Alzheimer's disease
3 ай бұрын
Harnessing resilience mechanisms to prevent neuronal loss in Alzheimer's disease
1:27
Harnessing resilience mechanisms to prevent neuronal loss in Alzheimer's disease
3 ай бұрын
Пікірлер